TheraCryf plc (LSE:TCF), a UK biotechnology company focused on treatments for addiction and neuropsychiatric conditions, is progressing a pipeline led by a novel orexin-1 receptor antagonist targeting binge eating, alcohol dependence, and substance use disorders. The group is also developing a dopamine transporter modulator for fatigue linked to brain disorders, alongside a legacy oncology programme, all within a capital-light model that prioritises partnerships following early clinical validation.
The company has now filed a new process patent covering key elements of the manufacturing method for its lead candidate, Ox-1. If granted, the patent could provide up to 20 years of additional protection, extending exclusivity beyond the existing composition of matter patent. This development strengthens the intellectual property position around Ox-1, increasing barriers to generic competition and enhancing the programme’s long-term commercial potential as it approaches clinical readiness later in 2026.
More about TheraCryf plc
TheraCryf plc is a UK-based biotechnology company developing therapies for addiction and other central nervous system disorders with significant unmet need. Its lead programme focuses on a best-in-class orexin-1 receptor antagonist designed to treat conditions such as binge eating and substance use disorders. The company also advances a dopamine transporter modulator for fatigue associated with conditions including multiple sclerosis, chemotherapy, and narcolepsy, as well as a legacy glioblastoma project. Operating under a virtual development model, TheraCryf aims to progress assets to early clinical or proof-of-concept stages before partnering with larger pharmaceutical companies.
Leave a Reply